L. Hartman

发表

Medication adherence in older people with rheumatoid arthritis is lower according to electronic monitoring than according to pill count

C. Allaart, W. Lems, M. Boers, 2021, Rheumatology.

AB0160 HIGH NUMBER OF CONCOMITANT MEDICATIONS AND COMORBIDITIES AT BASELINE IN THE GLUCOCORTICOID LOW-DOSE OUTCOME IN RHEUMATOID ARTHRITIS (GLORIA) STUDY: AN OLDER POPULATION WITH RHEUMATOID ARTHRITIS

C. Allaart, M. Boers, F. Buttgereit, 2021, Annals of the Rheumatic Diseases.

Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial

C. Allaart, W. Lems, M. Boers, 2022, Annals of the Rheumatic Diseases.

Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+: The pragmatic, multicenter, placebo-controlled GLORIA trial.

M. Boers, F. Buttgereit, R. Bos, 2022, Seminars in arthritis and rheumatism.

Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids

W. Lems, M. Boers, F. Buttgereit, 2022, Rheumatology.

The GLORIA adherence subproject: problems and randomization mistakes

C. Allaart, M. Boers, M. Kok, 2021, Journal of Trial and Error.

Outcome measures for adherence data from a medication event monitoring system: A literature review

W. Lems, M. Boers, L. Hartman, 2018, Journal of clinical pharmacy and therapeutics.

Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial

W. Lems, M. Boers, S. Ralston, 2018, Trials.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial

M. Boers, F. Buttgereit, R. Ionescu, 2019, Scandinavian journal of rheumatology.

Favourable effect of a ‘second hit’ after 13 weeks in early RA non-responders: the Amsterdam COBRA treat-to-target randomized trial

P. Kerstens, W. Lems, M. Boers, 2022, Rheumatology.

Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trial

C. Allaart, W. Lems, M. Boers, 2023, Annals of the Rheumatic Diseases.

Safety and efficacy associated with long-term low dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.

M. Boers, J. Kirwan, F. Buttgereit, 2023, Rheumatology.

The Effect of Low-Dose Glucocorticoids Over Two Years on Weight and Blood Pressure in Rheumatoid Arthritis: Individual Patient Data From Five Randomized Trials

M. Boers, J. Kirwan, F. Buttgereit, 2023, Annals of Internal Medicine.